Phase II trial of intravenous administration of reolysin ® (reovirus serotype-3-dearing strain) in patients with metastatic melanoma

Molecular Therapy

Volumn 20, Issue 10, 2012, Pages 1998-2003

  Galanis, Evanthia ^a   Markovic, Svetomir N ^a   Suman, Vera J ^a   Nuovo, Gerard J ^b   Vile, Richard G ^a   Kottke, Timothy J ^a   Nevala, Wendy K ^a   Thompson, Michael A ^a   Lewis, Jean E ^a   Rumilla, Kandelaria M ^a   Roulstone, Victoria ^c   Harrington, Kevin ^c   Linette, Gerald P ^d   Maples, William J ^a   Coffey, Matt ^e   Zwiebel, James ^f   Kendra, Kari ^b  

^a MAYO CLINIC   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d WASHINGTON UNIVERSITY   (United States)

^e ONCOLYTICS BIOTECH INC   (Canada)

^f CTEP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; ONCOLYTIC REOVIRUS SEROTYPE 3 DEARING STRAIN; ONCOLYTIC VIRUS; REOLYSIN; TUBULIN; UNCLASSIFIED DRUG; VIRUS ANTIGEN;

ADULT; AGED; ANEMIA; ANIMAL CELL; ANOREXIA; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; CANCER SURGERY; CLINICAL ARTICLE; CONFUSION; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; HYPERCALCEMIA; HYPERURICEMIA; HYPOALBUMINEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INDUCED HYPOTHERMIA; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; METASTATIC MELANOMA; MOUSE; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; PHASE 2 CLINICAL TRIAL; REOVIRUS; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR GROWTH; TUMOR NECROSIS; VIRUS REPLICATION; VOMITING;

ORTHOREOVIRUS; RNA VIRUSES;

EID: 84867027824     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.146     Document Type: Article

References (36)

1. Tyler, KL and Fields, BN. Reoviruses. In: Fields BN, Knipe DM, Chancock RM (eds). Virology, 2nd edn. Raven Press: New York, 1990, pp 1307-1328.
2. Bodkin, DK, Nibert, ML and Fields, BN (1989). Proteolytic digestion of reovirus in the intestinal lumens of neonatal mice. J Virol 63: 4676-4681.
3. Rosen, L, Evans, HE and Spickard, A (1963). Reovirus infections in human volunteers. Am J Hyg 77: 29-37.
4. Rubin, DH, Kornstein, MJ and Anderson, AO (1985). Reovirus serotype 1 intestinal infection: a novel replicative cycle with ileal disease. J Virol 53: 391-398.
5. Strong, JE, Coffey, MC, Tang, D, Sabinin, P and Lee, PW (1998). The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J 17: 3351-3362.
6. Wolf, JL, Kauffman, RS, Finberg, R, Dambrauskas, R, Fields, BN and Trier, JS (1983). Determinants of reovirus interaction with the intestinal M cells and absorptive cells of murine intestine. Gastroenterology 85: 291-300.
7. Chapman, PB, Hauschild, A, Robert, C, Haanen, JB, Ascierto, P, Larkin, J et al.; BRIM-3 Study Group. (2011). Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-2516.
8. Robert, C, Thomas, L, Bondarenko, I, O'Day, S, M D, JW, Garbe, C et al. (2011). Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364: 2517-2526.
9. Kaufman, HL and Bines, SD (2010). OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma. Future Oncol 6: 941-949.
10. Senzer, NN, Kaufman, HL, Amatruda, T, Nemunaitis, M, Reid, T, Daniels, G et al. (2009). Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol 27: 5763-5771.
11. Breitbach, CJ, Burke, J, Jonker, D, Stephenson, J, Haas, AR, Chow, LQ et al. (2011). Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 477: 99-102.
12. Nazarian, R, Shi, H, Wang, Q, Kong, X, Koya, RC, Lee, H et al. (2010). Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468: 973-977.
13. Errington, F, White, CL, Twigger, KR, Rose, A, Scott, K, Steele, L et al. (2008). Infammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma. Gene Ther 15: 1257-1270.
14. Qiao, J, Wang, H, Kottke, T, White, C, Twigger, K, Diaz, RM et al. (2008). Cyclophosphamide facilitates antitumor effcacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res 14: 259-269.
15. Gollamudi, R, Ghalib, MH, Desai, KK, Chaudhary, I, Wong, B, Einstein, M et al. (2010). Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs 28: 641-649.
16. Vidal, L, Pandha, HS, Yap, TA, White, CL, Twigger, K, Vile, RG et al. (2008). A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 14: 7127-7137.
17. Kapadia, R and Coffey, MC (2010). The use of immunohistochemistry to determine oncolytic reovirus distribution and replication in-human tumors. Methods 52: 301-306.
18. Farsetta, DL, Chandran, K and Nibert, ML (2000). Transcriptional activities of reovirus RNA polymerase in recoated cores. Initiation and elongation are regulated by separate mechanisms. J Biol Chem 275: 39693-39701.
19. Parker, JS, Broering, TJ, Kim, J, Higgins, DE and Nibert, ML (2002). Reovirus core protein mu2 determines the flamentous morphology of viral inclusion bodies by interacting with and stabilizing microtubules. J Virol 76: 4483-4496.
20. Pandha, HS, Heinemann, L, Simpson, GR, Melcher, A, Prestwich, R, Errington, F et al. (2009). Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res 15: 6158-6166.
21. Sei, S, Mussio, JK, Yang, QE, Nagashima, K, Parchment, RE, Coffey, MC et al. (2009). Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Mol Cancer 8: 47.
22. Comins, C, Spicer, J, Protheroe, A, Roulstone, V, Twigger, K, White, CM et al. (2010). REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res 16: 5564-5572.
23. Lolkema, M P, Arkenau, HT, Harrington, K, Roxburgh, P, Morrison, R, Roulstone, V et al. (2011). A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res 17: 581-588.
24. Karapanagiotou, EM, Roulstone, V, Twigger, K, Ball, M, Tanay, M, Nutting, C et al. (2012). Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res 18: 2080-2089.
25. White, CL, Twigger, KR, Vidal, L, De Bono, JS, Coffey, M, Heinemann, L et al. (2008). Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther 15: 911-920.
26. Jackson, GG and Muldoon, RL (1973). Viruses causing common respiratory infections in man. J Infect Dis 127: 328-355.
27. Minuk, GY, Paul, RW and Lee, PW (1985). The prevalence of antibodies to reovirus type 3 in adults with idiopathic cholestatic liver disease. J Med Virol 16: 55-60.
28. Minuk, GY, Rascanin, N, Paul, RW, Lee, PW, Buchan, K and Kelly, JK (1987). Reovirus type 3 infection in patients with primary biliary cirrhosis and primary sclerosing cholangitis. J Hepatol 5: 8-13.
29. Stanley, NF (1974). The reovirus murine models. Prog Med Virol 18: 257-272.
30. Prestwich, RJ, Errington, F, Steele, LP, Ilett, EJ, Morgan, RS, Harrington, KJ et al. (2009). Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J Immunol 183: 4312-4321.
31. Prestwich, RJ, Ilett, EJ, Errington, F, Diaz, RM, Steele, L P, Kottke, T et al. (2009). Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin Cancer Res 15: 4374-4381.
32. Steele, L, Errington, F, Prestwich, R, Ilett, E, Harrington, K, Pandha, H et al. (2011). Pro-infammatory cytokine/chemokine production by reovirus treated melanoma cells is PKR/NF-?B mediated and supports innate and adaptive anti-tumour immune priming. Mol Cancer 10: 20.
33. Therasse, P, Arbuck, SG, Eisenhauer, EA, Wanders, J, Kaplan, RS, Rubinstein, L et al. (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216.
34. Nuovo, GJ (2010). In situ detection of microRNAs in paraffn embedded, formalin fxed tissues and the co-localization of their putative targets. Methods 52: 307-315.
35. Nuovo, GJ, Elton, TS, Nana-Sinkam, P, Volinia, S, Croce, CM and Schmittgen, TD (2009). A methodology for the combined in situ analyses of the precursor and mature forms of microRNAs and correlation with their putative targets. Nat Protoc 4: 107-115.
36. Limsui, D, Vierkant, RA, Tillmans, LS, Wang, AH, Weisenberger, DJ, Laird, PW et al. (2010). Cigarette smoking and colorectal cancer risk by molecularly defned subtypes. J Natl Cancer Inst 102: 1012-1022.